KOSDAQ Biotech ETFs Attract Investors Amid Growth and Volatility
The Korean stock market continues to see a robust performance in the biotech sector, leading to rapid expansion of the KOSDAQ biotech ETF space. There are now 42 listed healthcare and biotech ETFs, up by more than 10 from last year, with the RISE BioTOP10 Active ETF recording a notable three-month return of 23%. Active ETFs are particularly successful in these volatile conditions, quickly adjusting to market changes, while some, such as the TIGER BioTOP10, have underperformed due to declines in core holdings.
Significant capital inflows into biotech ETFs have been observed recently, with investors viewing these funds as both defensive and growth assets when diversifying their portfolios. The listing of active KOSDAQ ETFs is also expected to reshape the investment landscape for the biotech industry. Both Samsung Active Asset Management and Timefolio Asset Management have launched ETFs featuring different biotech constituents and weighting strategies, with Qurient and Samchundang Pharm selected as flagships for each fund, respectively. The sharp rise in Qurient’s share price on the ETF’s listing day drew notable investor attention, but sustained inflows to the KOSDAQ market will depend on how biotech competes against other growth sectors.
Related ETF
Related News
Holding Strong Amid High Volatility... Bio ETF Active Strategy Worked - MaekyungIn conjunction with KOSDAQ activation policies, 10 new Bio ETFs emerged over the past year. KB Asset Management's 'RISE Bio TOP10' has an impressive 23% return in three months, attracting attention with active capital inflow.
Related ETF
KOSDAQ Active ETFs Focusing on Bio…Curient and Samchundang Pharmaceutical Catch AttentionWith the listing of the KOSDAQ Active Exchange-Traded Fund (ETF) on the 10th, changes are being detected in the bio investment landscape. Depending on each management firm's portfolio strategy, the incorporated stocks and their proportions vary significantly, emerging as a new factor in bio demand. KoAct targets Curient, and TIME focuses on Samchundang...